B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design

B cells are believed to be central to the disease process in systemic lupus erythematosus (SLE), making them a target for new therapeutic intervention. In recent years there have been many publications regarding the experience in SLE of B-cell depletion utilising rituximab, an anti-CD20 mAb that tem...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy, Venkat, Jayne, David, Close, David, Isenberg, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624107/
https://www.ncbi.nlm.nih.gov/pubmed/23566295
http://dx.doi.org/10.1186/ar3910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624107/
https://www.ncbi.nlm.nih.gov/pubmed/23566295
http://dx.doi.org/10.1186/ar3910

Ejemplares similares